Rutgers Researchers Develop New MRSA Prodrug: Can the Pathogen Gain Resistance?
AUG 16, 2017 | CONTAGION® EDITORIAL STAFF
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, breaks down the process of how Staphylococcus aureus (S. aureus) is able to gain resistance to methicillin. Dr. Pilch also explains if the pathogen can gain resistance to a new prodrug he helped develop: TXA709.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512